Treace Medical Concepts, Inc.
HealthcareNASDAQ:TMCI · NASDAQ Global Select
+$0.15 today
Vol 1.00M · Avg 0.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-67.6%
avg -121.9%
ROIC
-33.9%
avg -20.4%
ROA
-31.0%
avg -20.1%
Analysis
ROA is currently the strongest return metric at -31.0% versus its period average of -20.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
John T. Treace | Founder, Chairman & Chief Executive Officer | $770,190.00 | — | 54 | $7.38M | 11.37% |
Mark L. Hair | Chief Financial Officer | $524,796.00 | — | 56 | $952,002.00 | 1.47% |
Brad Barr | Senior Vice President of Sales | $484,223.00 | — | — | — | — |
Gaetano Guglielmino | Chief Commercial Officer | $468,536.00 | — | 56 | $490,901.00 | 0.76% |
Sean F. Scanlan | Chief Innovation & Marketing Officer | $461,207.00 | — | 44 | $704,677.00 | 1.09% |
Scot Elder | Chief Legal & Compliance Officer and Corporate Secretary | $446,933.00 | — | 51 | $794,936.00 | 1.23% |
Daniel E. Owens | Chief Human Resources Officer | — | — | 54 | $176,375.00 | 0.27% |
Taylor Erickson | Chief Information & Cybersecurity Officer | — | — | — | — | — |
Terry W. Lubben | Chief Operations & Supply Chain Officer | — | — | 61 | $25,800.00 | 0.04% |
Zac Potter | Senior VP & Chief Accounting Officer | — | — | — | — | — |
Rachel Osbeck | Chief Regulatory & Continuous Improvement Officer | — | — | — | — | — |
Shana Zink | Senior Vice President of Clinical Affairs & Reimbursement | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
11
$1.20M
Sells
0
$0.00
Net Sentiment
+$1.20M
Net buying
Most Active
Treace John T.
11 transactions
1–10 of 11
Analysis
Insiders reported 11 buys worth $1.20M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $1.20M. Treace John T. was the most active insider with 11 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +48.3% | +4.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +48.3% over three years. Forward estimates point to Revenue at +4.9% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Enhabit, Inc.
EHAB
$706.91M
CeriBell, Inc.
NASDAQ:CBLL
$700.80M
Surmodics, Inc.
SRDX
$614.51M
Bioventus Inc.
NASDAQ:BVS
$576.54M
The Oncology Institute, Inc.
NASDAQ:TOI
$530.91M
OrthoPediatrics Corp.
NASDAQ:KIDS
$457.71M
Evolus, Inc.
NASDAQ:EOLS
$443.20M
Standard BioTools Inc.
NASDAQ:LAB
$346.53M
Semler Scientific, Inc.
SMLR
$310.75M
RxSight, Inc.
NASDAQ:RXST
$194.98M
Who manages TMCI?
Treace Medical Concepts, Inc. (TMCI) lists 12 active executives. The top listed executive is John T. Treace, Founder, Chairman & Chief Executive Officer.
Are TMCI insiders buying or selling?
Recent insider activity shows net selling of $20.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.